Oculis Holding AG (OCS) Cash & Current Investments (2021 - 2026)
Oculis Holding AG's (OCS) quarterly Cash & Current Investments came in at $283.5 million in Q1 2026, up 40.12% year-on-year from $202.3 million in Q1 2025, and up 6.39% quarter-over-quarter from $266.5 million in Q4 2025.
Oculis Holding AG (OCS) Cash & Current Investments (2021 - 2026) Analysis & Trends
Oculis Holding AG's Cash & Current Investments history runs 6 years deep, the most recent figure standing at $283.5 million for Q1 2026.
- On a quarterly basis, Cash & Current Investments rose 40.12% year-over-year to $283.5 million in Q1 2026; TTM through Mar 2026 was $283.5 million, a 40.12% increase from a year earlier, with the FY2025 full-year figure at $256.9 million, up 129.09% from the prior year.
- Cash & Current Investments climbed to $283.5 million in Q1 2026 per OCS's latest filing, from $266.5 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $283.5 million in Q1 2026 and bottomed at -$51.1 million in Q3 2023.
- The 5-year median for Cash & Current Investments is $121.7 million (2024), against an average of $115.5 million.
- Across the five-year window, Cash & Current Investments tumbled 186.92% in 2023 and jumped 730.86% in 2024, its largest moves.
- Year by year, Cash & Current Investments stood at $20.5 million in 2022, then sank by 186.92% to -$17.9 million in 2023, then soared by 730.86% to $112.6 million in 2024, then surged by 136.64% to $266.5 million in 2025, then grew by 6.39% to $283.5 million in 2026.
- Per Business Quant, the three latest OCS Cash & Current Investments figures stand at $283.5 million (Q1 2026), $266.5 million (Q4 2025), and $181.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 283.54 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 5.18 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 37.29 Bn | 34.28 Bn | 959.66 Mn | 3.01 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 283.54 Mn |
| Dec 31, 2025 | 266.52 Mn |
| Sep 30, 2025 | 181.49 Mn |
| Jun 30, 2025 | 193.62 Mn |
| Mar 31, 2025 | 202.35 Mn |
| Dec 31, 2024 | 112.63 Mn |
| Sep 30, 2024 | 121.74 Mn |
| Jun 30, 2024 | 130.40 Mn |
| Mar 31, 2024 | 91.58 Mn |
| Dec 31, 2023 | -17.85 Mn |
| Sep 30, 2023 | -51.11 Mn |
| Jun 30, 2023 | -33.53 Mn |
| Dec 31, 2022 | 20.54 Mn |
| Dec 31, 2021 | 50.19 Mn |